Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2025 May 1;15(5):3942-3949.
doi: 10.21037/qims-24-1880. Epub 2025 Apr 27.

Depicting growth characteristics with computed tomography for KRAS-mutated lung adenocarcinoma

Ernuo Wang #  1 , Yiyi Gao #  1 , Fang Lu  1 , Wufei Chen  1 , Haiquan Liu  1
Affiliations

Depicting growth characteristics with computed tomography for KRAS-mutated lung adenocarcinoma

Ernuo Wang et al. Quant Imaging Med Surg. .

Abstract

Background: Kirsten rat sarcoma viral oncogene homolog (KRAS) is a key oncogenic driver in lung adenocarcinoma (LUAD). The correlation between KRAS mutations and the computed tomographic (CT) texture features in LUAD patients is not well established. This study aimed to investigate the relationship between the CT texture features of LUAD and the KRAS mutation.

Methods: This study included 808 LUAD patients who were diagnosed with the KRAS mutation and underwent surgical resection at the Huadong Hospital. Of the 808 patients, 720 had preoperative chest CT data, which were collected for retrospective analysis. Further, all the CT images of lesions were classified into different categories based on the CT texture features. Moreover, the association between KRAS status and the clinical features and CT texture features was evaluated.

Results: The results revealed that KRAS mutations were more common in the male patients than the female patients [8.5% (29/341) vs. 2.4% (11/467), P<0.0001] and were more frequent in the older patients than the younger patients [6.5% (29/448) vs. 3.1% (11/360), P=0.02]. The CT texture feature of mixed ground-glass opacity (mGGO) indicated a lower incidence of KRAS mutations than the CT texture features of pure ground-glass opacity (pGGO) [1.3% (3/232) vs. 6.7% (15/225), P=0.0032] and pure solid opacity (pSO) [1.3% (3/232) vs. 6.1% (16/263), P=0.0056]. Moreover, a comparison of the frequency of pGGOs and pSOs ≤1 cm showed that the frequency of PGOs was higher than that of pSOs for KRAS mutations vs. wild type, but the statistical significance was marginal [12.0% (11/92) vs. 0% (0/27), P=0.05].

Conclusions: This study revealed that KRAS mutations were more common in male and older LUAD patients. Further, in most LUAD patients with KRAS mutations, pGGOs changed into pSOs at the size of >1 cm at least.

Keywords: Kirsten rat sarcoma viral oncogene homolog (KRAS); Lung adenocarcinoma (LUAD); computed tomography (CT); smoking; texture.

PubMed Disclaimer

Conflict of interest statement

Conflicts of Interest: All authors have completed the ICMJE uniform disclosure form (available at https://qims.amegroups.com/article/view/10.21037/qims-24-1880/coif). The authors have no conflicts of interest to declare.

Figures

Figure 1
Figure 1
CT image of a 53-year-old female LUAD patient with the KRAS mutation. CT scan showed a pGGO with a diameter of 7 mm in the left inferior lobe. CT, computed tomography; KRAS, Kirsten rat sarcoma viral oncogene homolog; LUAD, lung adenocarcinoma; pGGO, pure ground-glass opacity.
Figure 2
Figure 2
CT image of a 71-year-old male LUAD patient with the KRAS mutation. The CT scan showed a pSO with a diameter of 2.8 cm in the right upper lobe. CT, computed tomography; KRAS, Kirsten rat sarcoma viral oncogene homolog; LUAD, lung adenocarcinoma; pSO, pure solid opacity.
See this image and copyright information in PMC

Similar articles

See all similar articles

References

    1. Rosen JC, Sacher A, Tsao MS. Direct GDP-KRAS(G12C) inhibitors and mechanisms of resistance: the tip of the iceberg. Ther Adv Med Oncol 2023;15:17588359231160141. 10.1177/17588359231160141 - DOI - PMC - PubMed
    1. Fan F, Zhang H. A case description of pulmonary enteric adenocarcinoma with KRAS G12D mutation. Quant Imaging Med Surg 2023;13:8787-92. 10.21037/qims-23-369 - DOI - PMC - PubMed
    1. Gower A, Wang Y, Giaccone G. Oncogenic drivers, targeted therapies, and acquired resistance in non-small-cell lung cancer. J Mol Med (Berl) 2014;92:697-707. 10.1007/s00109-014-1165-y - DOI - PMC - PubMed
    1. Lindeman NI, Cagle PT, Beasley MB, Chitale DA, Dacic S, Giaccone G, Jenkins RB, Kwiatkowski DJ, Saldivar JS, Squire J, Thunnissen E, Ladanyi M, College of American Pathologists International Association for the Study of Lung Cancer and Association for Molecular Pathology . Molecular testing guideline for selection of lung cancer patients for EGFR and ALK tyrosine kinase inhibitors: guideline from the College of American Pathologists, International Association for the Study of Lung Cancer, and Association for Molecular Pathology. J Mol Diagn 2013;15:415-53. Erratum in: J Mol Diagn 2013;15:730.10.1016/j.jmoldx.2013.03.001 - DOI - PubMed
    1. Meng D, Yuan M, Li X, Chen L, Yang J, Zhao X, Ma W, Xin J. Prognostic value of K-RAS mutations in patients with non-small cell lung cancer: a systematic review with meta-analysis. Lung Cancer 2013;81:1-10. 10.1016/j.lungcan.2013.03.019 - DOI - PubMed

LinkOut - more resources